Open access

767 Interferon gamma reduces CAR-T exhaustion and toxicity without compromising therapeutic efficacy in hematologic malignancies
Stefanie Bailey, Sonika Vatsa, Amanda Bouffard, Rebecca Larson, Irene Scarfo, Michael Kann, Andrea Schmidts, Marcela Maus

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A459; DOI: 10.1136/jitc-2020-SITC2020.0767
771 Characterization of tumor infiltrating immune cells from adult soft tissue sarcomas
Jacky Chen, Jay Wunder, Nalan Gokgoz, Irene Andrulis

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A461-A463; DOI: 10.1136/jitc-2020-SITC2020.0771
770 Analysis of gut microbiome in patients receiving adoptive T-cell therapy (ACT) across different solid tumour types
Arantzazu Barquin Garcia, Sergio Ruiz, Paloma Navarro, Juan Francisco Rodriguez-Moreno, Elena Sevillano, Monica Yague, Sandra Amarilla, Jesus Garcia-Donas

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A461; DOI: 10.1136/jitc-2020-SITC2020.0770
773 Adoptive Cell Therapy Response in Melanoma is Mediated by Stem-like CD8 T cells
Sri Krishna, Frank Lowery, Amy Copeland, Stephanie Goff, Grégoire Altan-Bonnet, Paul Robbins, Steven Rosenberg

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A463-A464; DOI: 10.1136/jitc-2020-SITC2020.0773
772 A potent and off-the-shelf oNK cell therapy product targets HER2+ cancer cells and resists suppressive tumor microenvironment
Hao-Kang Li, Ching-Wen Hsiao, Sen-Han Yang, Hsiu-Ping Yang, Tai-Sheng Wu, Zih-Fei Cheng, Chia-Yun Lee, Yan-Liang Lin, Yan-Da Lai, Sai-Wen Tang, Janet Pan, Wei-Lun Lo, Shih-Chia Hsiao

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A463; DOI: 10.1136/jitc-2020-SITC2020.0772
774 Antibiotic administration prior to immunotherapy leads to poor overall survival across multiple malignancies
Eric Vick, Inas Abuali, Sarah Ludvigsen, Andrew Kelleher, Nathanael Moore, Nicholas Arias, Shuchi Gulati, Trisha Wise-Draper

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A464-A465; DOI: 10.1136/jitc-2020-SITC2020.0774
775 Rare case reports on thymic carcinoma patients treated with pembrolizumab
Evelyn Paszkan, Erna Ganofszky, Zsolt Megyesfalvi, Aron Ghimessy, Balazs Dome, Laszlo Agocs, Erika Toth, Ferenc Renyi-Vamos, Gabor Rubovszky

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A465; DOI: 10.1136/jitc-2020-SITC2020.0775
779 Immune checkpoint blockade impacts the suppressive phenotype and function of regulatory T cells in an endogenous mouse lymphoma model
Vera Bauer, Fatima Ahmetlic, Martin Roecken, Ralph Mocikat, Ralph Mocikat

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A467-A468; DOI: 10.1136/jitc-2020-SITC2020.0779
778 Preclinical study using a glutamatergic signaling and immune-checkpoint inhibitors in a spontaneous melanoma prone mouse model
Kevinn Eddy, Christina Marinaro, Maryam Rasheed, Joseph Campagnolo, Xiaoxuan Zhong, Mohamad Eddin, Raj Shah, Kajal Gupta, Jesus Diaz, Andrew Zloza, Suzie Chen

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A467; DOI: 10.1136/jitc-2020-SITC2020.0778
76 Potential mechanisms of resistance identified through analysis of multiple biomarkers in immune hot non-responders with non-small cell lung cancer (NSCLC) treated with tislelizumab
Jayesh Desai, Qing Zhou, Sanjeev Deva, Jun Zhao, Jie Wang, Wei Tan, Xiaopeng Ma, Yun Zhang, Zhirong Shen, Xikun Wu, Shiangjiin Leaw, Juan Zhang, Yi-Long Wu

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A47; DOI: 10.1136/jitc-2020-SITC2020.0076

Main menu

Open access

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Open access

Pages